Exploring semaglutide for alcohol use disorder: A review of clinical efficacy and neurobiological mechanisms
- Design
- Narrative review · Mixed outcome
- Match to healthy normal-weight adults aged 55–75
- Partial matchPARTIAL: the review covers people selected for alcohol use disorder rather than for obesity or diabetes, with several included cohorts enriched for obesity; age, BMI and diabetes status are not given.
- Could weight loss explain it?
- PossiblyPossibly: the authors themselves list potential confounding from weight loss and note effects seemed strongest in people with obesity or metabolic disease; no separation of weight effects is reported.
- Study tier
- Not ratedNOT_RATED: a narrative review with no pooled estimate and no new primary data.
- Assessment
- Version 2 · Two reviewers differed; settled by a recorded ruling · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This narrative review gathered trials, real-world studies and laboratory work on semaglutide and alcohol use disorder. The authors report that trials found less craving and fewer drinks per drinking day with semaglutide, that cohort studies linked it to fewer alcohol-related hospital stays, and that effects looked strongest in people with obesity or metabolic disease. They stress that the evidence is early, based on small and short studies, possibly confounded by weight loss, and that no GLP-1 drug is approved for this use.
01Findings
What the study reported
- Drugs
- Semaglutide, Tirzepatide
- Comparator
- non-users (cohort studies); comparator in the randomised trials not stated
- Primary outcome
- alcohol craving, consumption and AUD-related hospitalisation
- Effect
- Included RCTs reported reduced alcohol craving and drinks per drinking day with semaglutide; cohort studies linked semaglutide to fewer AUD-related hospitalisations; tirzepatide linked to lower binge-drinking odds and AUDIT scores; no numeric estimates in the abstract
- 95% confidence interval
- not reported in abstract
- Follow-up
- Not stated
- Adverse events
- not reported in abstract
- Limitations
- The authors note small samples, brief follow-up, self-reported outcomes and possible confounding by weight loss, and that trials in AUD-only populations are still needed; non-systematic study selection.
Who was studied
- Obesity status
- mixed (several cohorts enriched for comorbid obesity)
- Diabetes status
- not reported in abstract
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- alcohol use disorder, including non-treatment-seeking individuals
- Inclusion exclusion
- studies chosen for clinical relevance to AUD outcomes and mechanisms
Study quality details
- Study design
- Narrative review
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- n/a
- Comparator
- non-users (cohort studies); comparator in the randomised trials not stated
- Follow up duration
- not stated
- Outcome type
- mixed
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- PARTIAL
- Statistical precision
- no CI or pooled estimate reported
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- Authors declare no known competing financial interests or personal relationships.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[AIMS] To examine emerging clinical evidence, real-world data, and neurobiological mechanisms supporting the repurposing of semaglutide as a novel treatment for alcohol use disorder (AUD) METHODS: Of records identified, articles were selected based on clinical relevance to AUD outcomes and mechanisms of action. Included studies ranged from hypothesis-generating designs to confirmatory randomized controlled trials in non-treatment-seeking individuals and patients diagnosed with AUD, with several cohorts enriched for comorbid obesity. [RESULTS] Randomized controlled trials demonstrated that once-weekly semaglutide significantly reduced alcohol cravings and drinks per drinking day, even in non-treatment-seeking populations. Large-scale cohort studies showed a reduction in AUD-related hospitalizations for patients on semaglutide compared to non-users. Dual agonists like tirzepatide also showed significant reductions in binge drinking odds and AUDIT scores, with reductions in alcohol craving and consumption appearing most pronounced among individuals with comorbid obesity or metabolic disease. Mechanistically, preclinical and early human data indicate GLP-1 receptor activity in the VTA and nucleus accumbens modulates mesolimbic reward circuitry to attenuate dopamine-mediated reinforcement, alongside indirect behavioral and satiety effects. [CONCLUSIONS] GLP-1 receptor agonists show early promise in reducing alcohol craving and consumption, particularly in individuals with comorbid metabolic disease. No GLP-1 receptor agonist currently carries FDA approval for alcohol use disorder, and all discussed clinical applications still remain investigational. Definitive randomized trials in AUD-only populations are still needed. Current evidence remains limited by small sample sizes, brief follow-up periods, self-reported outcomes, and potential confounding from weight loss.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Oct 18, 2026 | 42880142 first ingestion |